tesofensine
Sign in to saveTesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
~6 min read
Encyclopedic overview
8 sectionsContents
- History
- Pharmacology
- Metabolism and half-life
- Transporter selectivity
- Clinical trials
- Adverse events
- See also
- References
Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
As of 2019, tesofensine has been discontinued for the treatment of Alzheimer's and Parkinson's disease but is in phase III clinical trial for obesity.
Excerpted from Wikipedia’s “tesofensine” article, available under the CC BY-SA 4.0 licence.